Charles River Laboratories International, Inc. Aktie News

WILMINGTON, Mass. & OKLAHOMA CITY--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler's Portable CMC® (Chemistry, Manufacturing a...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-qualit...

Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript

Charles River Laboratories forecast full-year profit above Wall Street estimates on Wednesday after the contract researcher beat quarterly revenue and profit expectations, helped by the recent acquisition of Noveprim.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance.

WILMINGTON, Mass.--(BUSINESS WIRE)--Building upon its flagship Endosafe® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their recombinant cascade reagent (rCR) to launch the Endosafe® Trillium™ rCR cartridge offering. Expanding its robust bacterial endotoxin testing (BET) portfolio with a new an...

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call.